Molecular Neurobiology

, Volume 40, Issue 1, pp 33–45

Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors


DOI: 10.1007/s12035-009-8067-y

Cite this article as:
Thomas, E.A. Mol Neurobiol (2009) 40: 33. doi:10.1007/s12035-009-8067-y


Histone deacetylase (HDAC) inhibitors represent a promising new avenue of therapeutic options for a range of neurological disorders. Within any particular neurological disorder, neuronal damage or death is not widespread; rather, particular brain regions are preferentially affected. Different disorders exhibit distinct focal pathologies. Hence, understanding the region-specific effects of HDAC inhibitors is essential for targeting appropriate brain areas and reducing toxicity in unaffected areas. The outcome of HDAC inhibition depends on several factors, including the diversity in the central nervous system expression of HDAC enzymes, selectivity of a given HDAC inhibitor for different HDAC enzymes, and the presence or absence of cofactors necessary for enzyme function. This review will summarize brain regions associated with various neurological disorders and factors affecting the consequences of HDAC inhibition.


HDAC inhibitor CNS Therapeutic Specificity Epigenetic Histone deacetylase Clinical Neurodegenerative 

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Department of Molecular BiologyThe Scripps Research InstituteLa JollaUSA

Personalised recommendations